https://revbio.com/, https://tetranite-vet.com/

RevBio, Inc., 600 Suffolk Street, Lowell, MA (2026)

05/12/2026

The RevBio team had a fantastic time at the 2026 Annual Meeting in San Antonio last week. Thank you to the many attendees who came by our booth to learn about TETRANITE®, our regenerative bone adhesive technology. It was a pleasure to share how our innovative biomaterial will reduce the duration and complexity of neurosurgical procedures, allow for more minimally invasive surgeries, lessen patient pain and recovery time, and reduce the overall cost of care with clinicians and leaders in the neuro community.

Key conversations with new connections from AANS were focused on RevBio’s exciting clinical progress updates. Our upcoming multi-center randomized controlled pivotal clinical trial will determine the safety and efficacy of TETRANITE® to reintegrate cranial bone flaps. Read more about this upcoming trial, here: https://www.businesswire.com/news/home/20260127271652/en/FDA-Greenlights-RevBios-Pivotal-Clinical-Trial-for-its-Cranial-Flap-Bone-Glue

05/02/2026

RevBio is at the 2026 Annual Meeting this weekend in San Antonio, TX! Our team will share how ® regenerative bone adhesive is transforming the future of skull-based procedures at booth 1113 in the exhibit hall. Attendees will get a chance to experience the unique properties of the biomaterial; especially how easy it is to apply and how strong the glue is in fixating cranial flaps compared to plates and screws.

AANS featured speaker and RevBio’s CMO Dr. Kevin Foley, will be presenting throughout the weekend. See the full program schedule, here: https://aans2026.eventscribe.net/

Happy to be here in Texas!

ClinicalTrials MedicalDevice CranialFlapFixation BoneAdhesive RegenerativeMedicine FDA

03/12/2026

The RevBio team completed three successful industry conference stops on the “2026 Bone Glue Roadshow” where they showcased TETRANITE® in various late-stage clinical trials! Head to our LinkedIn to read the full post!

CEO Brian Hess and Director of Product and Clinical Development, Brittany McDonough, kicked off the week by attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans. The focus of this conference was to raise awareness and build excitement for our upcoming clinical pilot study to evaluate TETRANITE for extremity fracture fixation.

The next stop was the Academy of Osseointegration (AO) 2026 Annual Meeting in Washington, DC. The team hosted an evening event where clinicians and industry leaders were able to learn about the various TETRANITE® applications, both within the dental space and beyond. Special emphasis was placed around building excitement for our pivotal study for dental implant stabilization. Day two of the meeting featured a Town Hall presentation by RevBio CFO/COO D. Grayson Allen, Sr. Director of Dental Clinical Operations, Dr. Alan Pollack, and Marketing Director, Michael Tiedemann. Thank you to everyone who attended our event and presentation—what a great turn out!

The team’s travels concluded with the North American Skull Base Society ( ) 2026 Annual Meeting in San Diego, California. CEO Brian Hess, VP of R&D Michael Brown, Clinical Development Specialist, Gracie Cleaver, and Marketing Specialist, Erica Malho, manned the booth and provided TETRANITE® product demonstrations to interested clinicians. Attendees were excited to learn about our upcoming pivotal clinical trial which will evaluate TETRANITE to fixate cranial flaps after craniotomy procedures.

And the momentum isn’t slowing down! We thank our team and collaborators for their continued efforts… RegenerativeBoneAdhesive

03/05/2026

This weekend, RevBio will be presenting and exhibiting at the North American Skull Base Society 2026 Annual Meeting in sunny San Diego, California.

For those attending, join us at booth #107 to learn how TETRANITE® regenerative bone adhesive is transforming the future of skull-based procedures by eleminating the need for metal hardware. You will get a chance to experience the unique properties of the bone glue by witnessing a product demonstration. See how easy TETRANITE is to apply and how strong our adhesive is in fixating cranial flaps compared to standard plates and screws. We will also be holding conversations with clinicians who are interested in becoming investigators in our upcoming pivotal clinical trial for cranial flap fixation.

Gracie Cleaver, RevBio’s Clinical Development Specialist, will be presenting a poster highlighting a TETRANITE® use case from our recent Cranial Flap Fixation Pilot Trial in collaboration with Mass General Brigham. Be sure to stop by and check out this exciting poster presentation!
Exhibit hall and Poster Presentation hours:

• Friday 3/6: 9:00am–4:00pm, 6:05pm–. 7:35pm
• Saturday 3/7: 9:00am–4:00pm

We look forward to representing RevBio at NASBS along with the latest scientific research, education, and best practices in skull base surgery.

02/02/2026

What a great time at the Yankee Dental Congress in Boston last week!

RevBio was one of only five companies to be featured in the “Liquid Gold Exhibit” by Revere Partners. This exhibit highlighted cutting-edge startups driving the future of dentistry. We had meaningful conversations with attendees regarding how TETRANITE® is disrupting to the standard of care in dentistry, as well our Series A funding round. The team also demonstrated two TETRANITE dental products: Implant Stabilization Material and Adhesive Dental Bone Scaffold.

It was great seeing some familiar faces, including RevBio Dental Advisor Board member Dr. Alvaro Gracia and Bruce Kennedy from our Dental Sales Team.

Thank you to everyone who stopped by to connect and learn how TETRANITE is transforming dentistry for clinicians and patients alike. And a big thanks to Revere Partners and Jeremy N. Krell, DMD, MB for having us!

01/28/2026

RevBio® is proud to announce another watershed moment for our Cranial Flap Fixation program—FDA has greenlighted us for a pivotal clinical trial!

The company has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use ® to reintegrate cranial bone flaps, which are portions of the skull that are temporarily removed by neurosurgeons to perform brain surgery.

“This regenerative adhesive has the potential to fundamentally change how cranial reconstruction is performed. It enhances structural integrity, promotes fusion, reduces wound complications, and delivers markedly improved cosmetic outcomes,” said Timothy Smith, MD, PhD, MPH, Director, Computational Neuroscience Outcomes Center and practicing neurosurgeon at Brigham and Women’s Hospital in Boston, Massachusetts.

Check out the full press release, here–https://www.businesswire.com/news/home/20260127271652/en/FDA-Greenlights-RevBios-Pivotal-Clinical-Trial-for-its-Cranial-Flap-Bone-Glue

Craniotomy Cranioplasty Kerf Fixation RegenerativeMedicine BoneRegeneration ClinicalTrial PivotalTrial NovelTechnology FDA IDEapproval

01/02/2026

Happy New Year from RevBio! Take a look at our monthly highlights from 2025. 🎉

We are excited to carry the momentum from this past year right into 2026!

Our team is laser-focused on continuing the clinical evaluation on our leading indications consisting of cranial flap fixation, dental implant stabilization, extremity fracture fixation, and dental bone grafting. The regulatory process continues to validate TETRANITE®’s safety and efficacy as the only regenerative bone glue.

2026 promises to be a watershed year for raising capital to scale patient enrollment and complete our ongoing FDA approved pivotal trials.

We would like to thank our employees, investors, and collaborators for another successful year of working towards commercialization of the revolutionary TETRANITE® product platform.

12/22/2025

RevBio® is pleased to announce the recent approval from FDA to start a new dental clinical trial for ®, our novel regenerative bone glue. This clinical trial for ridge augmentation procedures expands the portfolio of indications for TETRANITE.

This product development program was funded since its inception by several successive grants totaling $1.8 million from the Translational Resource Center (TRC), a research consortium (U24-DE029462) funded by the National Institute of Dental and Craniofacial Research (NIDCR at NIH)) to improve the translation of promising tissue engineering and regenerative medicine technologies.

To read more about this highly anticipated upcoming clinical trial, please read the full press release here: https://www.businesswire.com/news/home/20251219800454/en/RevBio-Receives-Approval-from-FDA-to-Start-a-Dental-Clinical-Trial-for-its-Regenerative-Bone-Glue

BoneAdhesive TETRANITEit TransformingBoneRepair Bioengineeringabodyofapplications Dental DentalBoneGrafting RidgeAugmentation Craniofacial FDA PilotStudy ClinicalTrial HumanTrials NIDCR NIH

12/09/2025

RevBio is excited to share that CEO Brian Hess and CFO Grayson Allen will be representing the company at the 2025 New England Venture Summit, hosted by youngStartup Ventures.

We’re honored to have been selected to present TETRANITE®, our groundbreaking regenerative bone glue, as a significant investment opportunity to an audience of venture capitalists, corporate and private investors, investment bankers, and strategic partners across the MedTech industry. With our pivotal clinical trial for cranial flap fixation on the horizon, the time is now to focus our efforts on raising Series A capital to bring our game-changing technology to market supported by the promising pilot study results.

Don’t miss CEO Brian Hess on the MedTech Track as he showcases RevBio’s clinical trial updates and the TETRANITE product pipeline on Wednesday, December 10th at 11:40 AM EST in the New England Suite.

Recognized as a premier gathering for innovators and investors, NEVS brings together leaders seeking new opportunities, strategic visibility, and growth. Learn more about Young Startup Ventures and register for upcoming events here: https://www.youngstartup.com

11/18/2025

CEO Brian Hess and CFO Grayson Allen represented RevBio at the Musculoskeletal New Ventures Conference (MNVC) in Memphis, TN. While there, Brian shared exciting company updates and presented clinical trial progress across a range of indications to an audience of surgeons, investors, and industry leaders. Easily injectable into a range of musculoskeletal defects, TETRANITE® has demonstrated superior clinical performance over current standard of care options including curing speed, shear forces, rate of bone regeneration, and most critically, wet-field adhesion.

This marks RevBio’s fifth year attending MNVC, a cornerstone event for innovation in the musculoskeletal field. We’re always inspired by the opportunity to connect, collaborate, and explore the latest advancements shaping the future of musculoskeletal health. Thank you to Gary Stevenson and HealthpointCapital for organizing this great event.

11/04/2025

RevBio® is thrilled to announce TETRANITE®, the company’s first of its kind regenerative “bone glue” has been approved for a 20-patient pilot study to measure the biomaterial’s safety and efficacy to treat complex, multi-fragmented wrist fractures including those that involve articular surfaces. This important milestone marks a significant step forward in RevBio’s Extremity Fracture Fixation program, paving the way for more patients to benefit from this revolutionary biomaterial.

“Having used TETRANITE in pre-clinical testing, I am extremely impressed that RevBio has been able to create the first superglue for bone repair,” said Jesse B. Jupiter , MD, former Hansjorg Wyss AO Professor of Orthopedic Surgery at Harvard Medical School, and advisor to RevBio. “Throughout my entire career, the orthopaedic surgeon community and I have long sought a solution to give patients with such complex fractures faster and more predictable recovery.”

Explore the interactive press, featuring video content and a look into the peer-reviewed science behind TETRANITE®. Link in our bio!

RevBio, Inc.

05/12/2026

05/02/2026

03/12/2026

03/05/2026

02/02/2026

01/28/2026

01/02/2026

12/22/2025

12/09/2025

11/18/2025

11/04/2025

Address

Website

Alerts

Shortcuts

Share

Category